恩格列净与利拉鲁肽或西格列汀在具有多样患者特征的老年人中的比较有效性
该回顾性比较有效性队列研究利用2014年8月1日至2018年9月30日的Medicare索赔数据,纳入65岁以上2型糖尿病患者,采用1:1倾向评分匹配分别比较恩格列净 vs 利拉鲁肽(队列1,45 788例)和恩格列净 vs 西格列汀(队列2,45 624例)。结果显示,恩格列净较利拉鲁肽降低心衰住院风险(HR 0.66;95%CI 0.52-0.82),改良MACE风险相似(HR 0.90;95%CI 0.79-1.03);较西格列汀降低改良MACE风险(HR 0.68;95%CI 0.60-0.77)和心衰住院风险(HR 0.45;95%CI 0.36-0.56)。合并ASCVD、HF或CKD者绝对获益更大。提示老年T2D患者在心衰住院方面可能更多获益于恩格列净。
要点
- 老年T2D患者中,恩格列净较利拉鲁肽降低心衰住院风险(HR 0.66;95%CI 0.52-0.82),改良MACE风险相似(HR 0.90;95%CI 0.79-1.03)。
- 恩格列净较西格列汀降低改良MACE风险(HR 0.68;95%CI 0.60-0.77)和心衰住院风险(HR 0.45;95%CI 0.36-0.56),各亚组一致。
- 恩格列净 vs 西格列汀的绝对获益在合并ASCVD、HF或CKD者更大:HF者改良MACE的RD -41.1(95%CI -59.9至-22.6),HHF的RD -50.4(95%CI -67.5至-33.9)。
- 恩格列净 vs 利拉鲁肽的改良MACE风险存在性别异质性(男性HR 0.85 [95%CI 0.71-1.01];女性HR 1.16 [95%CI 0.94-1.42];同质性P=0.02)。
- 作者认为,老年T2D患者在心衰住院风险方面可能更多获益于恩格列净而非利拉鲁肽或西格列汀;在MACE风险方面,恩格列净可能仅在有心血管疾病史者优于利拉鲁肽,而在所有亚组均优于西格列汀。
适用人群与场景
- 纳入年龄大于65岁的2型糖尿病Medicare按服务收费受益人,使用2014年8月1日至2018年9月30日的去标识化索赔数据。
- 队列1为启动恩格列净或利拉鲁肽的倾向评分匹配患者(22 894对,共45 788例);队列2为启动恩格列净或西格列汀的倾向评分匹配患者(22 812对,共45 624例)。
- 随访从启动药物开始,直至治疗改变、死亡或Medicare参保中断超过30天。
研究设计与关键结果
- 研究类型为回顾性比较有效性队列研究,使用Medicare索赔数据;队列1平均(SD)年龄71.9(5.1)岁,女性23 396例(51.1%),男性22 392例(48.9%),白人38 049例(83.1%);队列2平均(SD)年龄72.1(5.1)岁,女性21 418例(46.9%),男性24 206例(53.1%),白人37 814例(82.9%)。
- 恩格列净 vs 利拉鲁肽:改良MACE风险相似(HR 0.90;95%CI 0.79-1.03);心衰住院风险降低(HR 0.66;95%CI 0.52-0.82)。
- 恩格列净 vs 利拉鲁肽亚组:有ASCVD史者改良MACE风险降低(HR 0.83;95%CI 0.71-0.98);有HF史者改良MACE风险降低(HR 0.77;95%CI 0.60-1.00);按性别存在潜在异质性(男性HR 0.85 [95%CI 0.71-1.01];女性HR 1.16 [95%CI 0.94-1.42];同质性P=0.02);心衰住院风险在多数亚组降低(如ASCVD:HR 0.66 [95%CI 0.51-0.85];HF:HR 0.66 [95%CI 0.49-0.88])。
- 恩格列净 vs 西格列汀:改良MACE风险降低(HR 0.68;95%CI 0.60-0.77);心衰住院风险降低(HR 0.45;95%CI 0.36-0.56);各亚组结果一致。
- 恩格列净 vs 西格列汀绝对获益(RD/1000人年):有ASCVD史者改良MACE -17.6(95%CI -24.9至-10.4),心衰住院 -16.7(95%CI -21.7至-11.9);有HF史者改良MACE -41.1(95%CI -59.9至-22.6),心衰住院 -50.4(95%CI -67.5至-33.9);有CKD者改良MACE -26.7(95%CI -41.3至-12.3),心衰住院 -31.9(95%CI -43.5至-20.8)。
证据类型、等级与局限
- 证据类型:回顾性比较有效性队列研究,使用Medicare索赔数据,采用1:1倾向评分匹配调整143个基线协变量。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,老年T2D患者在心衰住院风险方面可能更多获益于恩格列净而非利拉鲁肽或西格列汀;在MACE风险方面,恩格列净可能仅在有心血管疾病史者优于利拉鲁肽,而在所有患者亚组均优于西格列汀。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Limited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum of cardiorenal risk.
OBJECTIVE: To evaluate the association of empagliflozin with cardiovascular outcomes relative to liraglutide and sitagliptin, stratified by age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD).
DESIGN, SETTING, AND PARTICIPANTS: This retrospective comparative effectiveness cohort study used deidentified Medicare claims data from August 1, 2014, to September 30, 2018, with follow-up from drug initiation until treatment changes, death, or gap in Medicare enrollment (>30 days). Data analysis was performed from October 1, 2021, to April 30, 2022. Medicare fee-for-service beneficiaries older than 65 years with T2D were included. A total of 45 788 patients (22 894 propensity score-matched pairs initiating treatment with either empagliflozin or liraglutide) were included in cohort 1, and 45 624 patients (22 812 propensity score-matched pairs initiating treatment with either empagliflozin or sitagliptin) were included in cohort 2.
EXPOSURES: Empagliflozin vs liraglutide (cohort 1) or empagliflozin vs sitagliptin (cohort 2).
MAIN OUTCOMES AND MEASURES: Primary outcomes were (1) modified major adverse cardiovascular events (MACEs), including a composite of myocardial infarction, stroke, and all-cause mortality, and (2) hospitalization for heart failure (HHF). Hazard ratios (HRs) and rate differences (RDs) per 1000 person-years were estimated, adjusting for 143 baseline covariates using 1:1 propensity score matching.
RESULTS: Among 45 788 patients in cohort 1, the mean (SD) age was 71.9 (5.1) years; 23 396 patients (51.1%) were female, 22 392 (48.9%) were male, and 38 049 (83.1%) were White. Among 45 624 patients in cohort 2, the mean (SD) age was 72.1 (5.1) years; 21 418 patients (46.9%) were female, 24 206 (53.1%) were male, and 37 814 (82.9%) were White. Relative to patients initiating liraglutide, those initiating empagliflozin had a similar risk of the modified MACE outcome (HR, 0.90; 95% CI, 0.79-1.03) and a reduced risk of HHF (HR, 0.66; 95% CI, 0.52-0.82). Across subgroups, empagliflozin was associated with a lower risk of the modified MACE outcome in patients with a history of ASCVD (HR, 0.83; 95% CI, 0.71-0.98) and HF (HR, 0.77; 95% CI, 0.60-1.00) compared with liraglutide, and potential heterogeneity in estimates was observed by sex (male: HR, 0.85 [95% CI, 0.71-1.01]; female: HR, 1.16 [95% CI, 0.94-1.42]; P = .02 for homogeneity). However, reductions in the risk of HHF were observed across most subgroups (eg, ASCVD: HR, 0.66 [95% CI, 0.51-0.85]; HF: HR, 0.66 [95% CI, 0.49-0.88]). Compared with sitagliptin, empagliflozin was associated with reduced risks of the modified MACE outcome (HR, 0.68; 95% CI, 0.60-0.77) and HHF (HR, 0.45; 95% CI, 0.36-0.56), which were consistent across all subgroups. Absolute benefits of empagliflozin vs sitagliptin were larger in patients with a history of ASCVD (modified MACE: RD, -17.6 [95% CI, -24.9 to -10.4]; HHF: RD, -16.7 [95% CI, -21.7 to -11.9]), HF (modified MACE: RD, -41.1 [95% CI, -59.9 to -22.6]; HHF: RD, -50.4 [95% CI, -67.5 to -33.9]), or CKD (modified MACE: RD, -26.7 [95% CI, -41.3 to -12.3]; HHF: RD, -31.9 [95% CI, -43.5 to -20.8]).
CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study of older adults, empagliflozin was associated with a lower risk of HHF (relative to both liraglutide and sitagliptin) and the modified MACE outcome (relative to sitagliptin), with larger absolute benefits in patients with established cardiorenal diseases. These findings suggest that older adults with T2D might benefit more from empagliflozin vs liraglutide or sitagliptin with respect to the risk of HHF; with respect to the risk of MACEs, empagliflozin might be preferable to liraglutide only in patients with cardiovascular disease history and to sitagliptin across all patient subgroups.
参考来源
- Htoo PT, Tesfaye H, Schneeweiss S, et al. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics. JAMA Netw Open. 2022. PMID: 36264574. doi:10.1001/jamanetworkopen.2022.37606
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。